About Seattle Genetics
The online programme is sponsored by Seattle Genetics.
Seattle Genetics, an innovative international biotechnology company, develops and commercialises antibody-based therapies for cancer. Our industry-leading antibody-drug conjugates harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. We have a robust pipeline designed to address unmet needs and improve outcomes for patients. Seattle Genetics is headquartered in the US, with European and International operations in Switzerland.